PURPOSE: Tumor-infiltrating macrophages are associated with adverse outcome in adult classical Hodgkin lymphoma (cHL). We have previously shown age-related changes in the lymphocyte composition of pediatric cHL. We therefore hypothesized that the number, function, and prognostic impact of macrophages in pediatric cHL would be different from adult cases. EXPERIMENTAL DESIGN: We analyzed the number of macrophages and dendritic cells (DC) in the tumor microenvironment of pediatric cHL by immunohistochemistry. Results were analyzed in context of age, histologic characteristics, Epstein-Barr virus (EBV) status, clinical follow-up, and our previous study of T-cell populations in these cases. RESULTS: One hundred cHL cases were studied, including 69% nodular sclerosis and 23% mixed cellularity cases. A total of 44.8% of cases were EBV-positive. Patients ≤10 years displayed more CD14(+) cells (P = 0.025). In comparison with nodular sclerosis, mixed cellularity was characterized by higher numbers of CD14(+), (P = 0.003) and CD163(+) cells (P = 0.027). EBV(+) cases exhibited higher numbers of CD14(+) (P < 0.0005), CD68(+) (P = 0.005), and CD163(+) cells (P = 0.02). CD68-positive cells did not display an effect on outcome. Worse overall survival was observed in cases with CD163/CD8 ratio ≥2 (P = 0.007). High numbers of CD163(+) cells were associated with worse progression-free survival (PFS; P = 0.015). Furthermore, high numbers of CD163(+) and granzyme B(+) cells were associated with worse PFS in EBV-negative (P = 0.005) but not in EBV-positive cases. CONCLUSION: Our results suggest that macrophage composition in pediatric cHL is distinct from adults. Functional status of macrophages and their value as prognostic indicators in pediatric cHL may depend on EBV status.
PURPOSE:Tumor-infiltrating macrophages are associated with adverse outcome in adult classical Hodgkin lymphoma (cHL). We have previously shown age-related changes in the lymphocyte composition of pediatric cHL. We therefore hypothesized that the number, function, and prognostic impact of macrophages in pediatric cHL would be different from adult cases. EXPERIMENTAL DESIGN: We analyzed the number of macrophages and dendritic cells (DC) in the tumor microenvironment of pediatric cHL by immunohistochemistry. Results were analyzed in context of age, histologic characteristics, Epstein-Barr virus (EBV) status, clinical follow-up, and our previous study of T-cell populations in these cases. RESULTS: One hundred cHL cases were studied, including 69% nodular sclerosis and 23% mixed cellularity cases. A total of 44.8% of cases were EBV-positive. Patients ≤10 years displayed more CD14(+) cells (P = 0.025). In comparison with nodular sclerosis, mixed cellularity was characterized by higher numbers of CD14(+), (P = 0.003) and CD163(+) cells (P = 0.027). EBV(+) cases exhibited higher numbers of CD14(+) (P < 0.0005), CD68(+) (P = 0.005), and CD163(+) cells (P = 0.02). CD68-positive cells did not display an effect on outcome. Worse overall survival was observed in cases with CD163/CD8 ratio ≥2 (P = 0.007). High numbers of CD163(+) cells were associated with worse progression-free survival (PFS; P = 0.015). Furthermore, high numbers of CD163(+) and granzyme B(+) cells were associated with worse PFS in EBV-negative (P = 0.005) but not in EBV-positive cases. CONCLUSION: Our results suggest that macrophage composition in pediatric cHL is distinct from adults. Functional status of macrophages and their value as prognostic indicators in pediatric cHL may depend on EBV status.
Authors: Aldana G Vistarop; Melina Cohen; Fuad Huaman; Lucia Irazu; Marcelo Rodriguez; Elena De Matteo; María Victoria Preciado; Paola A Chabay Journal: Med Microbiol Immunol Date: 2018-07-25 Impact factor: 3.402
Authors: Paola Ghione; Alison J Moskowitz; Nadia E K De Paola; Steven M Horwitz; Marco Ruella Journal: Curr Hematol Malig Rep Date: 2018-12 Impact factor: 3.952
Authors: Rebecca L Johnston; Anja Mottok; Fong Chun Chan; Aixiang Jiang; Arjan Diepstra; Lydia Visser; Adèle Telenius; Randy D Gascoyne; Debra L Friedman; Cindy L Schwartz; Kara M Kelly; David W Scott; Terzah M Horton; Christian Steidl Journal: Blood Date: 2022-02-10 Impact factor: 25.476
Authors: Jennifer A Kanakry; Hailun Li; Lan L Gellert; M Victor Lemas; Wen-son Hsieh; Fangxin Hong; King L Tan; Randy D Gascoyne; Leo I Gordon; Richard I Fisher; Nancy L Bartlett; Patrick Stiff; Bruce D Cheson; Ranjana Advani; Thomas P Miller; Brad S Kahl; Sandra J Horning; Richard F Ambinder Journal: Blood Date: 2013-02-05 Impact factor: 22.113
Authors: Ann-Kathrin Desch; Kristin Hartung; Ante Botzen; Alexander Brobeil; Mathias Rummel; Lars Kurch; Thomas Georgi; Theresa Jox; Stefan Bielack; Stefan Burdach; Carl Friedrich Classen; Alexander Claviez; Klaus-Michael Debatin; Martin Ebinger; Angelika Eggert; Jörg Faber; Christian Flotho; Michael Frühwald; Norbert Graf; Norbert Jorch; Udo Kontny; Christof Kramm; Andreas Kulozik; Joachim Kühr; Karl-Walter Sykora; Markus Metzler; Hermann L Müller; Michaela Nathrath; Thomas Nüßlein; Michael Paulussen; Arnulf Pekrun; Dirk Reinhardt; Harald Reinhard; Claudia Rössig; Axel Sauerbrey; Paul-Gerhardt Schlegel; Dominik T Schneider; Wolfram Scheurlen; Lothar Schweigerer; Thorsten Simon; Meinolf Suttorp; Peter Vorwerk; Roland Schmitz; Regine Kluge; Christine Mauz-Körholz; Dieter Körholz; Stefan Gattenlöhner; Andreas Bräuninger Journal: Leukemia Date: 2019-08-20 Impact factor: 11.528